92% probability Danaher's Q3 2026 core revenue growth lands at or above 1.0% — a floor a full point below the bottom of its own 2–3% guidance, in a life-sciences business still absorbing a respiratory-testing headwind. Resolves ~20 Oct 2026.
Danaher reported Q2 2026 revenue of $6.3bn, up 5.5%, with non-GAAP core revenue growth of 3.0% (4.5% excluding respiratory testing) and adjusted EPS of $1.94. It guided Q3 core revenue growth to 2–3% and full-year 2026 to 3.0–4.0%, while raising full-year adjusted EPS guidance to $8.45–$8.60. Source: Danaher Q2 2026 results, 21 July 2026.
We lock a binary: Danaher reports third-quarter 2026 non-GAAP core revenue growth of at least 1.0% year-on-year. Confidence 92%.
Danaher guided Q3 core revenue growth to 2–3% and raised full-year EPS guidance in the same release, which is not the behaviour of a business expecting the quarter to fall apart. Its revenue base is heavily recurring — consumables and service into installed instrument bases — which is what makes a growth floor forecastable at all. Our floor sits a full point below the bottom of that guide. Confidence 92%, not higher, because the stock fell 15% on the Q2 release despite the raise, and bioprocessing demand has been the sector's volatile variable. The trap worth naming: the same release reports core revenue growth of 3.0% AND core revenue growth excluding respiratory testing of 4.5%. We lock the FIRST — the headline core figure — and say so, because a point-and-a-half gap between two similarly-named numbers is exactly where a scoring dispute would live.
RAOSCAFF locks P-207 on 2026-08-26, before the Q3 release. Scored against Danaher's reported third-quarter 2026 non-GAAP core revenue growth versus a 1.0% floor.
The stock fell 15% on the Q2 release despite a guidance raise; bioprocessing demand is the sector's volatile variable.